Management of patients with issues related to opioid safety, efficacy and/or misuse: a case series from an integrated, interdisciplinary clinic by William C. Becker et al.
Becker et al. Addict Sci Clin Pract  (2016) 11:3 
DOI 10.1186/s13722-016-0050-0
CASE STUDY
Management of patients with issues 
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misuse: a case series from an integrated, 
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Abstract 
Background: Patients, providers, communities and health systems have struggled to achieve balance between 
access to opioid treatment for chronic pain and its potential harmful consequences: especially misuse, addiction and 
overdose. We developed an interdisciplinary clinic embedded within primary care (the Opioid Reassessment Clinic—
ORC) with the goal of improving the quality of care of patients with co-occurring chronic pain and issues related to 
opioid safety, efficacy and/or misuse.
Case descriptions: We present three cases referred to the ORC that highlight complex clinical scenarios related to 
assessment and treatment of patients with chronic pain and issues related to opioid safety, efficacy and misuse.
Discussion and evaluation: In the context of the three cases, with respect to assessment, we discuss: making the 
diagnosis of opioid use disorder; allowing the patient space to endorse lack of efficacy; identification of co-occurring 
hazardous alcohol use; and recognizing barriers to multimodal pain care. With respect to treatment, we discuss: mak-
ing a change in treatment with which the patient may not agree; effectiveness of buprenorphine/naloxone for the 
treatment of chronic pain; responding to low efficacy; and making continued opioid therapy contingent on engage-
ment with substance abuse treatment.
Conclusions: The core components of our approach—biopsychosocial assessment and multimodal treatment plan-
ning with an emphasis on promoting functional goals and safety using clear communication and a patient-centered 
stance—should guide providers in the management of similar clinical scenarios. More evidence is needed to defini-
tively guide specific interventions and points of clinical equipoise.
Keywords: Chronic pain, Opioid use disorder, Prescription drug misuse, Opioid safety, Interdisciplinary care, 
Integrated care
© 2016 Becker et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
While rates of opioid prescribing for pain may have 
reached a plateau in the US, adverse outcomes related 
to opioid therapy, most notably unintentional over-
dose deaths, remain a serious public health problem [1]. 
Patients, providers, communities and health systems have 
struggled to achieve balance between access to opioid 
treatment for chronic pain and potential harmful conse-
quences of long term opioid therapy, especially misuse, 
addiction and overdose. Regulatory agencies and expert 
groups have published prescriber guidelines aimed at 
improving uptake of evidence-based practices including: 
(1) use of opioid treatment agreements; (2) regular moni-
toring for efficacy, safety and misuse using tools such 
urine drug testing and querying prescription monitoring 
databases; and (3) provision of or referral to addiction 
treatment if recurrent misuse or opioid use disorder is 
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identified [2, 3]. These are becoming the standard of care 
for individuals on long-term opioid therapy.
In practice, primary care providers (PCPs), responsible 
for most of chronic pain management and opioid pre-
scribing in the US, struggle to follow these guidelines, 
citing lack of clinic time for opioid management, inad-
equate training, and low confidence [4]. Use of opioid 
risk mitigation strategies has been low in primary care 
[5], even among patients at high risk for misuse [6]. It is 
therefore understandable that the most complex cases—
those in which individuals on long-term opioids, often at 
high doses, have persistently poor function, exhibit con-
cerning behaviors such as running out of opioids early, 
or develop a substance use disorder to an opioid or other 
drug—are extremely challenging to manage in primary 
care. Notably, even among experts in the field, there is no 
consensus regarding how to best address these clinical 
situations.
In an effort to support primary care in the manage-
ment of patients with complex chronic pain on long-term 
opioid therapy, a multi-disciplinary team designed the 
Opioid Reassessment Clinic (ORC) at VA Connecticut 
Healthcare System [7]. (Co-author JSM directs a chronic 
pain clinic for individuals with HIV, with a similar scope 
of practice as the ORC [8]).
Embedded within primary care and staffed by an addic-
tion psychiatrist, an internist with addiction and pain 
training, a behavioral health advanced practice nurse 
(APRN) and a clinical health psychologist, the ORC has 
served as a learning opportunity for management of 
complex chronic pain and opioids over the past 3 years. 
The purpose of this study is to present actual ORC cases 
(with some details changed to preserve anonymity) as a 
platform to describe our approach to assessment and 
treatment, with the goal of highlighting evidence-based 
practices as well as some approaches we employ based 
on pragmatic considerations where evidence is lacking. 
While not intended to be a comprehensive clinical dis-
cussion of each case, our aim is to provide practicing cli-
nicians guidance on generalizable issues related to pain, 
opioid safety and addiction within each case. We intend 
the discussion in each case to be relevant to generalists 
and specialists alike.
ORC flow (see Fig. 1)
The team’s internist reviews all referrals and appropri-
ate patients are scheduled for an initial intake. The team’s 
APRN performs a chart review prior to the initial evalu-
ation covering information such as: summary of the 
consultation question, history of the pain complaint(s), 
engagement in multimodal pain treatment, current opi-
oid dose and prescriber, evidence of aberrant medica-
tion-taking behavior, mental health diagnosis and degree 
of engagement in treatment, past medical history, and 
overall utilization of health services.
The patient is scheduled for a 1.5–2-h initial evaluation—
the first part with the psychiatrist and subsequently, the 
internist. The psychiatric evaluation includes an assess-
ment of pain generators, current level of functioning 
and pain interference, current treatment approaches, 
functional goals as identified by the patient, and the use 
and effectiveness of opioids for the pain condition. A dis-
cussion of any noted aberrancies occurs and education 
about current best-practice pain treatment is initiated. 
Additionally, a targeted mental health and substance use 
history is gathered along with any other pertinent medi-
cal history. Following this evaluation, the team meets 
to discuss the case and an initial plan is developed. The 
team internist then meets with the patient to discuss gen-
eral impressions, perform a physical examination, elicit 
responses to any remaining questions, and collaborate 
with the patient in determining a plan.
An important point to emphasize in our general 
approach is the recognition that the intersection of 
Fig. 1 Opioid reassessment clinic flow
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chronic pain and opioid issues may be fraught with frus-
tration, mistrust and dissatisfaction for both patients 
and providers. In view of this, we place special empha-
sis on transparency and clear communication both 
with the patient and teams of providers involved in the 
patient’s care. When communicating a potential treat-
ment plan with the patient, we summarize our approach 
as the “7E’s”: empathize; elicit functional goals; educate; 
endorse an alternative plan consistent with patient’s 
functional goals; enlist patient’s buy-in; enact a follow-up 
plan; and equanimity. Anecdotally, we find this approach 
to increase the likelihood of preserving a therapeutic 
alliance and the patient’s engagement in the treatment 
process. In case 1, we include how this approach was 
employed, including specific useful phrases.
General ORC approach
Examples of typical reasons for referral to the ORC 
include: concerning medication-taking behaviors (e.g. 
request for an early refill or a urine drug screen with an 
unexpected result); sole reliance on opioids with limited 
or no engagement in other pain treatment modalities; 
unhealthy alcohol use; co-prescribed high-dose opioids 
and sedatives (most commonly benzodiazepines); sig-
nificant co-occurring mental health symptoms; and an 
opioid use disorder on medication assisted therapy (i.e. 
methadone or buprenorphine/naloxone) with persistent, 
impairing pain. While these issues are complex, the prin-
ciples we employ are the same standards for any patient 
with chronic pain, as described by the Institute of Medi-
cine: biopsychosocial assessment and multi-modal pain 
treatment matched to the needs identified in the assess-
ment [9]. As such, we structure each treatment plan 
around three core questions: What is the plan regarding 
opioid therapy?; What is the plan regarding multi-modal 
pain treatment?; and What is the plan regarding manage-
ment of co-occurring conditions that will impact the like-
lihood of success of the pain care plan? This framework, 
including opioid management options described below, 
and how it was applied in the three cases is presented in 
Table 1.
Emphasis on opioid safety
Regarding opioid therapy, typically three potential sce-
narios emerge from the initial assessment:
1. Misuse or safety without clear opioid use disorder: 
If misuse or safety are a concern, yet opioid use dis-
order is not clear, a trial of structured opioid therapy 
with or without an opioid dose reduction may be ini-
tiated. Structured opioid therapy consists of frequent 
monitoring of prescribed opioids as well as close 
follow-up of multimodal pain treatment engage-
ment, achievement of functional goals, mood and 
patterns of medication use [10]. If after 3–9 months, 
patients are able to demonstrate safe medication use, 
improved function, and engagement in multimodal 
treatment, they are discharged back to primary care 
for continued implementation of the pain care plan. 
On the other hand, if addiction to opioids or other 
substances is identified during this period of struc-
tured monitoring, patients are transitioned to addic-
tion treatment, including potentially initiation of 
buprenorphine/naloxone (BUP/NX) within ORC 
(both MDs are certified prescribers). If other safety 
issues emerge that do not require ongoing mainte-
nance therapy, an opioid taper is initiated.
2. Clear lack of efficacy: If lack of efficacy is apparent–
high levels of pain and limited or worsening function 
despite moderate or high dose opioids (≥50 mg mor-
phine equivalent daily dose), without evidence of opi-
oid misuse or addiction–opioid reduction is initiated, 
with the potential for complete discontinuation.
3. Clear opioid use disorder: If opioid use disorder is 
clear at the initial evaluation, a trial of medication 
assisted therapy (MAT) is provided either within our 
clinic (i.e. initiation of BUP/NX) or in a specialty SA 
treatment program.
Case 1 presentation
This is a 64-year-old patient with severe chronic obstruc-
tive pulmonary disease, post-traumatic stress disorder 
(PTSD) and degenerative joint disease of the lumbar 
spine, accompanied by many years of chronic pain and 
long-term high dose opioid therapy. Three months before 
ORC referral, the patient was admitted with recurrent 
hypercapneic respiratory failure, confusion, and a fall with 
head trauma. The inpatient team counseled the patient 
that high-dose opioid therapy (in the patient’s case 240 mg 
morphine equivalent daily dose [MEDD], well above the 
most common definition of high-dose therapy: ≥100 mg) 
likely contributed to these events and that dose lower-
ing or discontinuation would be necessary. The patient’s 
opioid dose was lowered on discharge; the patient’s sig-
nificant dissatisfaction with this decision prompted the 
PCP to refer the patient to the ORC. Over several visits to 
ORC spanning several months, we carefully observed the 
patient’s behavior relative to opioids. The patient repeat-
edly focused the conversation on opioids to the exclusion 
of other treatment modalities, and was largely unwilling 
to engage in discussions about the harms of opioids to his 
health. Providers’ attempts at patient-centered discussions 
to this end were met with escalating anger and agitation 
by the patient. Additionally, despite setting clear expecta-
tions and boundaries regarding how to take his medica-
tions, he ran out early twice during this time. As a result, 
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we made the diagnosis of mild opioid use disorder, elicited 
goals of care—to be more engaged with family and make 
more outings with them, and further assessed the patient 
as having marked deconditioning, poorly-controlled 
PTSD and non-engagement in evidence-based mental 
health and multi-modal pain treatments. We tapered the 
patient off of full agonist opioids, transitioning to BUP/
NX at 4/1 mg TID and delivered mental health, addiction, 
and multi-modal pain treatments within our clinic. Thrice 
daily dosing of BUP/NX is a common practice when the 
drug is used for pain as it is believed to have a 6–8 h anal-
gesic half-life [11].
Case 1 discussion
Assessment: making the diagnosis of opioid use disorder
As described by many experts in the field [12–14], assess-
ing the diagnostic criteria for opioid use disorder in a 
patient prescribed opioids for chronic pain can be chal-
lenging for a number of reasons. As per the DSM-5, tol-
erance (which this patient exhibited) and withdrawal 
symptoms cannot count towards the diagnosis in long-
term opioid therapy for pain since some degree of tol-
erance is expected and withdrawal symptoms would 
likely occur if opioids were abruptly discontinued. Also, 
patients may characterize aberrant medication-taking 
behaviors (e.g. taking more opioid than prescribed) as 
pain-relief-seeking whereas providers may view these 
as evidence of loss of control [15]. To disentangle this, 
we rely heavily on the use of clear communication with 
the patient on what constitutes safe use, using a written 
treatment agreement to document the discussion. We 
clearly state: “If you are unable to follow these rules, you 
will have demonstrated that opioid treatment is not safe 
for you and we will stop it.” We view a patient’s inabil-
ity to extinguish unsafe medication-taking behavior after 
he or she is aware that continued behavior will result in 
discontinuation of opioid therapy as, in and of itself, loss 
of control. Furthermore, recurrent behaviors inconsistent 
with the treatment agreement typically map onto DSM-5 
criteria for opioid use disorder. For example, in this case, 
we made the diagnosis of mild opioid use disorder based 
on our assessment of the presence of three diagnostic cri-
teria: craving, or a strong desire or urge to use opioids; 
recurrent opioid use in situations in which it was physi-
cally hazardous; and continued opioid use despite knowl-
edge of having a persistent physical and psychological 
problems that were likely to have been caused or exacer-
bated by use.
Treatment: making a change in treatment plan with which 
the patient may not agree
In this case, the presence of opioid use disorder and life-
threatening complications exacerbated by opioid therapy 
were two criteria for which ongoing opioid therapy were 
contraindicated. Prescribing full opioid agonists like oxy-
codone to someone with an opioid use disorder is explic-
itly discouraged by existing guidelines [16]. Despite this, 
providers in both the inpatient and outpatient settings 
continued full agonist opioid therapy for the treatment of 
pain; in our experience, this is not an uncommon occur-
rence. This paradox highlights the clinical challenges and 
uncertainties these situations present. We hypothesize 
that there are several reasons why physicians continue 
to prescribe full opioid agonists in individuals with opi-
oid use disorders. First, as above, opioid use disorder can 
be challenging to diagnose especially in individuals on 
long-term opioid therapy for chronic pain. Second, clini-
cal inertia—not making an indicated change in opioid 
regimen—may be partly driven by wanting to avoid con-
flict with the patient [17], who might have strong beliefs 
related to effectiveness and necessity of opioid therapy 
[18], and partly in general empathy towards the suffering 
of the patient [19].
Using the 7Es, we negotiated a switch to BUP/NX over 
several months. We expressed empathy by stating clearly, 
“We know your pain is real and can understand the 
thought of being in more pain is frightening and stress-
ful.” We elicited functional goals by asking, “What would 
you like to be able to do that pain is keeping you from 
doing these days?” In this case, the patient noted that 
he was not interacting with family as he wished. He was 
provided education about the risks of high dose opioids 
emphasizing those risks most relevant to him (i.e. res-
piratory failure) and given a description of what safe opi-
oid use would look like (not taking more than prescribed, 
only one pharmacy and provider, etc.) We endorsed an 
alternative plan of continuing the lowered opioid dos-
ing with engagement of multimodal treatment. We 
pointed out that his functional goal (family engagement) 
wasn’t being met with the high doses of opioids. Though 
sometimes counterintuitive to patients, we repeatedly 
reinforced the concept that his function might actually 
improve on lower doses once he was less sedated and 
having fewer medical emergencies. Also, over time, his 
pain might improve as well with lower opioid doses and 
engagement in multimodal pain care. Enlisting patient 
buy-in was difficult with this patient given his singular 
focus on obtaining higher doses of opioids. Nonethe-
less, we worked to increase the patient’s buy-in by pro-
viding him with options for treatment when available 
and sharing decisions when possible. While the “macro” 
treatment decision in this case (namely, discontinuing 
full agonist opioids) was not a shared decision, we find 
that when there are “micro” decisions where flexibility is 
possible (for example, frequency of BUP/NX dosing), let-
ting the patient’s preferences guide such decisions is an 
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important way to build trust and buy-in. Additionally, 
motivational interviewing, with its emphases on eliciting 
a person’s innate motivation and linking stated priori-
ties to positive behavior change, can be useful in secur-
ing patient buy-in. A follow up plan was enacted after 
discussion and agreement with the entire ORC team. In 
all of our interactions, we strive for equanimity. In this 
case, the patient was often upset with the team, believing 
he had been lied to about the possibility of going back on 
full agonist opioids, sometimes even screaming at pro-
viders. Having a team to process interactions and, when 
needed, to step in or provide follow up coverage has been 
helpful in maintaining calm and staying patient-centered 
in the face of patient emotions.
Treatment: effectiveness of BUP/NX for the treatment 
of chronic pain with co‑occurring OUD
While a full review is beyond the scope of this study, 
there are a number of observational studies [20] and 
case series [21–23] suggesting that BUP/NX can be an 
effective treatment for chronic pain. As with many pain 
treatments, predicting who will respond to BUP/NX has 
proved more challenging [24]. An important generaliz-
able point is that had the patient not tolerated BUP/NX, 
either because of poor efficacy or side effects, a return 
to full agonist opioids for the treatment of chronic pain 
would not have been offered because of the diagnoses of 
opioid use disorder and life-threatening opioid-related 
complications, unless the patient’s goals of care were to 
change to comfort measures.
Treatment: non‑opioid options
A wide array of generally safer non-opioid pharmacologic 
and non-pharmacologic options exist for managing this 
patient’s chronic pain, some of which have superior effi-
cacy data to support them. Along these lines, our mes-
sage to all patients in the ORC is as follows: the data are 
clear that a multi-modal pain management approach 
works best in the long-run for helping our patients 
achieve their functional goals; let us work with you to 
identify which combination will work best for you.
Case 1 epilogue: After transitioning to BUP/NX, the 
patient had three more hospital admissions for COPD 
exacerbation with marked hypercapnia and somnolence. 
Dose reduction was employed; however, even with BUP/
NX at 2  mg daily, markedly depressed sensorium was 
intermittently present. While non-adherence with home 
BiPAP and worsening COPD were perhaps most respon-
sible for this symptom, we felt that BUP/NX was at best 
not helping the situation, and at worst, could be contrib-
uting. Additionally, the patient did not report improved 
pain with BUP/NX. Thus, it was discontinued altogether. 
The patient remains on non-pharmacologic and non-opi-
oid pain treatments.
Case 2 presentation
This is a 65-year-old patient with widespread degenera-
tive joint disease and longstanding low back pain that 
has continued despite multiple cervical and lumbar sur-
geries and spinal cord stimulator placement. The PCP 
referred the patient to the ORC for consideration of an 
opioid rotation with dose reduction given tolerance to 
high doses of opioids (in this case, >200 mg MEDD). The 
patient was functionally quite active, pursuing an exer-
cise-based hobby that required regular travel, and had 
no history of unsafe opioid use or misuse. However, the 
patient reported that the opioid regimen did not improve 
pain to a significant degree; he continued it because he 
had been on it for so long and worried what would hap-
pen if he were to stop. Therefore, in our clinical assess-
ment, the patient did not have opioid use disorder, but 
would likely benefit—in terms of long-term safety—from 
decreasing the opioid dose. In the ORC, following a full 
assessment, the patient was provided a choice between 
(a) slow taper off opioids; (b) rotation to a different full 
agonist opioid but at a markedly lower dose; or (c) rota-
tion to a trial of BUP/NX for treatment of chronic pain. 
After a thorough discussion, the patient favored the latter 
option given significant ambivalence about being on full 
agonist opioids long-term.
Case 2 discussion
Assessment: allowing the patient space to endorse lack 
of efficacy
In our experience, some providers doubt that patients 
would endorse low or absent efficacy of long-term opi-
oids, since doing so would threaten ongoing receipt of 
opioids. However, in observational studies, a substantial 
minority of patients self-discontinue opioids due to lack 
of efficacy [25]. As illustrated by this case and prior lit-
erature [26], patients understandably fear the potential 
for withdrawal symptoms that often occurs when opioids 
are discontinued abruptly. We have observed that if con-
cerns about ongoing, high-dose opioid therapy are clearly 
explained, and patients are reassured that a taper would 
occur in a cautious, step-wise fashion with close over-
sight, patients seem open to disclosing lack of efficacy. 
Importantly, this patient discussed this with the PCP 
first, demonstrating that a specialist’s involvement was 
not needed upfront.
Treatment: responding to low efficacy
In our view, continuing ineffective opioid treatment 
is suboptimal, as it exposes the patient to cumulative 
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opioid toxicity (e.g. osteoporosis, hypogonadism, and fall 
risk) with no corresponding benefit. In contrast to case 
1, there was no evidence-guided indication for BUP/NX 
compared to rotation to a lower dose of a full agonist 
or taper off entirely, so the patient was given the choice. 
Also in contrast to case 1, had the trial of BUP/NX not 
succeeded, a return to full agonist opioids would have 
been considered, but, again, at a markedly lower dose. 
Of note, the use of BUP/NX in this setting is “off-label” 
insofar as it does not have FDA approval for treatment 
of chronic pain; however the DEA has endorsed such off-
label use [27].
Case 2 epilogue: The patient made the transition to 
BUP/NX easily, taking his initial dose at home. After the 
first 2  weeks, his dose was increased from 12  mg daily 
(divided 4  mg TID) to 18  mg because of inadequately 
controlled pain. His dose was ultimately increased to 
24 mg daily, yet he still experienced significant pain that 
was interfering with his function. The ORC team con-
sidered this a failed trial of BUP/NX and offered him the 
option to taper off BUP/NX with no opioid after versus 
rotation to lower dose oxycodone. The patient chose the 
latter option and is now on 10 mg oxycodone QID (60 mg 
MEDD), noting markedly improved pain control.
Case 3 presentation
This is a 56-year-old patient with bilateral hip pain due 
to severe osteoarthritis that significantly interfered 
with functioning for which the patient was prescribed 
morphine for several years. Nine months prior to ORC 
referral, the patient successfully completed a residen-
tial treatment program for his long-standing alcohol use 
disorder while continuing on long-term opioid therapy. 
Presently, the PCP referred the patient to the ORC after 
two episodes of running out of opioid prescriptions early 
(without early refill) and a brief return to alcohol use. In 
the ORC, we facilitated engagement in outpatient alcohol 
treatment by making continued opioid therapy contin-
gent upon adherence with follow-up and required fre-
quent ORC visits including breathalyzer tests and urine 
drug screens. Following another return to drinking, the 
patient was admitted to an intensive outpatient alcohol 
use disorder treatment program and was simultaneously 
tapered off morphine, transitioning to tramadol with 
adjuvant non-opioid medications including an NSAID, 
gabapentin, and topical lidocaine. While tramadol, a 
weak mu-receptor agonist with more prominent seroto-
nin and norepinephrine reuptake inhibition, was still a 
risky medication in this patient in recovery, it is classified 
by the DEA as less risky (schedule V compared to oxy-
codone and morphine’s schedule II designation); plus the 
patient’s tramadol dose was markedly lower in terms of 
mg MEDD.
Additionally, orthopedics was consulted and agreed 
to schedule hip replacement surgery contingent upon 
several months of documented alcohol abstinence. This 
motivated the patient to adhere to appointments and 
monitoring as required by both ORC and addiction treat-
ment providers. While the patient continued to request a 
switch to a “stronger” opioid, the ORC repeatedly reiter-
ated that this was not an option given the recent history 
of misuse, the lack of evidence of improved functioning 
on such medications, and benefit of being on the low-
est possible opioid dose prior to surgery. After 6 months 
of abstinence from alcohol, safe use of tramadol, and 
engagement in multimodal therapy including ongoing 
SA treatment, the patient was discharged from ORC to 
follow-up with PCP while awaiting scheduled surgery.
Case 3 discussion
Assessment: identification of co‑occurring hazardous alcohol 
use
In this case, there was a documented history of alcohol 
use disorder, alerting us from the outset to the need for 
ongoing and frequent monitoring of alcohol use. In this 
patient, alcohol abstinence was the goal so we employed 
breathalyzer testing at each office visit and added on 
ethyl glucuronide (EtG) testing to each urine drug screen. 
As a highly sensitive assay [28], we find EtGs especially 
helpful in documenting abstinence but less helpful when 
some alcohol use is acceptable (e.g. in patients on low-
dose opioid therapy without history of alcohol use disor-
der) and an easy test to incorporate into practice because 
the urine sample for the drug screen can be used. Relat-
edly, we believe alcohol abstinence should be a treat-
ment goal for any patient on moderate- to high-dose of 
opioid therapy (≥50  mg MEDD) since NIAAA guide-
lines recommend abstinence in patients taking medica-
tions that enhance central sedation (http://www.niaaa.
nih.gov/alcohol-health/overview-alcohol-consumption/
moderate-binge-drinking).
Assessment: recognizing barriers to multimodal pain care
Not infrequently, patients are ambivalent about the ben-
efits of multimodal care. In these instances, we employ 
education and motivational interviewing—components 
of the 7Es approach–in an attempt to help the patient 
recognize the discrepancy between their stated func-
tional goals and their plans to reach those goals. On the 
other hand, there are instances where misunderstanding 
of addiction by healthcare providers can prove its own 
barrier [29]. It is very reasonable for medical and surgi-
cal specialists to expect that addiction be treated prior 
to any invasive procedure. However, lack of collabora-
tion between specialists and PCPs often means delays for 
patients in getting appropriate and timely interventions.
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Treatment: making continued opioid therapy contingent 
on engagement with addiction treatment
As stated above, opioid therapy should never be the sole 
treatment modality in chronic pain. We consider optimi-
zation of medical and psychiatric co-morbidities a nec-
essary component of the multi-modal pain treatment 
approach. For example, attempts at optimization of dia-
betes control must accompany pain pharmacotherapy for 
the treatment of painful peripheral diabetic neuropathy. 
Analogously, we required engagement in addiction treat-
ment as a pre-condition for ongoing opioid therapy in 
this patient, not only to mitigate risk, but to maximize 
potential benefit of the pain care plan. This requirement 
is communicated upfront with the patient as part of the 
treatment agreement.
Case 3 epilogue: The patient underwent total hip 
replacement and received 2 weeks of full agonist opioid 
treatment (MSIR 15 mg Q6 PRN) following the surgery. 
After the 2-week post-operative period, the patient was 
transitioned back to tramadol. He remains abstinent 
from alcohol and participates fully in his hip rehabilita-
tion program.
Conclusions
These three cases from the ORC were meant to represent 
common challenges at the intersection between chronic 
pain and opioid safety, efficacy and misuse. We summa-
rized our approach related to several challenging issues 
regarding assessment and treatment. It is important to 
note that in this field where evidenced-based guidance is 
fairly sparse, the details of the treatment plans may vary 
from setting to setting. However, the core components–
biopsychosocial assessment and multimodal treatment 
planning with an emphasis on promoting functional goals 
and safety using clear communication and a patient-cen-
tered stance—should hold constant.
Additionally, we recognize that the majority of pain 
care in the US is provided by front-line PCPs, provid-
ers who may not feel that the management strategies 
presented here fall within their scope of practice. Even 
among pain specialists, comfort with identifying and 
addressing opioid use disorders may vary. Chronic pain 
and addiction specialists like we have on the ORC team 
are helpful in such situations, but are not widely available. 
Until a systematic change occurs to increase the availabil-
ity of such specialists, this disparity between need and 
availability will be present.
As the number of anecdotal recommendations above 
implied, there are several areas in this field where clinical 
research is needed: for example, comparative effective-
ness of various opioid tapering and rotation strategies; 
randomized studies of BUP/NX for the treatment of 
chronic pain; and motivational interviewing techniques 
for these common scenarios. Of note, work is underway 
by an expert consensus group (including authors JSM 
and WCB) to help define best practices in providers’ 
management of unsafe medication-taking behaviors [30]. 
And, finally, as called for by the Institute of Medicine [9], 
improved pain-related instruction in undergraduate and 
graduate medical education programs is also a high pri-
ority in the path towards improved quality of care.
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